Thermo Fisher (TMO) director gets 499-share award, 80 withheld for tax
Thermo Fisher Scientific director Dion J. Weisler received a grant of 499 shares of common stock. Concurrently, 80.287 shares were withheld at a price of $451.79 per share to cover tax obligations related to this award. Following these transactions, Weisler's direct holdings in Thermo Fisher amount to 4,947.384 shares.
Director at Thermo Fisher (NYSE: TMO) granted new shares
Thermo Fisher Scientific director, Scott M. Sperling, was granted 499 shares of common stock at no cost, which are compensation-related. Following this award, his direct holdings in TMO increased to 69,479 shares. The transaction, reported on a Form 4, indicates an acquisition rather than a market purchase or sale.
Thermo Fisher (NYSE: TMO) director receives 499-share stock award
Thermo Fisher Scientific director Jennifer M. Johnson was granted 499 shares of common stock, recorded at $0.00 per share, as part of her director compensation. This transaction, filed on Form 4, increased her direct holdings to 1,403 shares. The grant highlights stock-based compensation for directors, rather than an open-market purchase.
Director at Thermo Fisher (NYSE: TMO) awarded 499 common shares
Thermo Fisher Scientific director Harris C. Martin was awarded 499 shares of common stock on May 20, 2026, at no cash cost, which is a compensation-related grant. This transaction increased his direct holdings to 9,532 shares. The Form 4 filing indicates this was a grant, not an open-market purchase or sale.
Nuvation Bio (NUVB) Collaborates with Thermo Fisher
Nuvation Bio Inc. (NYSE:NUVB) completed the technology transfer and product introduction of IBTROZI-taletrectinib to Thermo Fisher Scientific for the treatment of ROS1-positive non-small cell lung cancer. The company recently reported Q1 EPS of 1c on revenue of $83.23M, surpassing consensus estimates. Nuvation Bio is also advancing safusidenib for IDH1-mutant glioma and expects to provide updates on its drug-drug conjugate platform later this year.
What Thermo Fisher CEO Said at Investor Day That the Market Is Still Processing
Thermo Fisher Scientific (TMO) held its 2026 Investor Day, where CEO Marc Casper and CFO Jim Meyer presented a case for a temporary market pain, emphasizing a structural opportunity despite academic and government funding suppression and a recent acquisition. Management reaffirmed a 7% long-term organic revenue CAGR by 2028, with current improvements in pharma and biotech sectors and potential upside from China and the NVIDIA partnership. The stock is trading near a multi-year valuation low, with analysts overwhelmingly rating it a Buy.
Research Tools & Consumables Stocks Q1 Results: Benchmarking Danaher (NYSE:DHR)
The article reviews the Q1 earnings of research tools & consumables stocks, highlighting mixed results across the sector. Danaher (NYSE:DHR) reported revenues slightly below expectations, leading to an 11.4% stock decline. In contrast, Waters Corporation (NYSE:WAT) significantly outperformed, while Revvity (NYSE:RVTY), Thermo Fisher (NYSE:TMO), and Avantor (NYSE:AVTR) also presented varying financial outcomes and market reactions.
Waters Corporation stock (US9418481035): diagnostics specialist in focus after Q1 2025 results
Waters Corporation, a key player in analytical instruments, reported higher Q1 2025 sales and earnings, driven by strong performance in its pharmaceutical and industrial segments. The company's business model relies on high-performance instruments, services, and consumables, with recurring revenue streams providing stability. For US investors, the stock offers exposure to pharmaceutical innovation and quality standards but carries risks related to competition, regulation, and macroeconomic factors.
Danaher Corp. stock (US2358511028): earnings beat keeps focus on life sciences recovery
Danaher Corp. reported a first-quarter 2026 earnings beat, exceeding Wall Street expectations, though revenue growth remained modest. The company's performance keeps investor attention on the recovery pace of its life sciences and diagnostics segments, which are crucial for its long-term growth. Danaher's diversified portfolio and strategic management system position it to capitalize on healthcare and scientific research trends, but near-term share price volatility reflects ongoing market sentiment concerns about demand in key end markets.
Thermo Fisher’s New Sweden Lab Deepens Role In Global Drug Development
Thermo Fisher Scientific has opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, bolstering its global drug development services, especially for complex modalities like antibodies and cell therapies. This move aims to deepen its role as a partner to pharmaceutical and biotech companies, expanding its reach in the Nordic region and reinforcing its competitive position against peers. Despite recent share price volatility and debt concerns, the company is investing in core drug development services, and investors should monitor the lab's utilization and its impact on long-term customer relationships.
Thermo Fisher Scientific stock (US8835561023): Earnings and lab demand in focus
This article focuses on Thermo Fisher Scientific (US8835561023) and its relevance for investors, highlighting the company's performance, demand drivers in lab instruments and services, and its role as a bellwether for US research spending. It details the company's core business model, key revenue streams, and what investors should monitor, such as instrument orders, consumables trends, and customer spending habits. The stock is presented as a crucial indicator for the broader life sciences infrastructure.
Shapiro Administration Highlights the Need for Funding to Grow Pennsylvania’s Innovation Economy During Visit to Thermo Fisher Scientific in Dauphin County
The Shapiro Administration is calling for increased funding to expand Pennsylvania's innovation economy, with Governor Josh Shapiro proposing nearly $100 million for the Innovate in PA 2.0 program in his 2026-27 state budget. This initiative aims to support key industries like life sciences, robotics, technology, energy, manufacturing, and agriculture, building on the state's historical leadership in discovery and innovation. During a visit to Thermo Fisher Scientific, DCED Secretary Rick Siger emphasized the importance of strategic investments to foster this vital ecosystem and attract industry leaders.
Should Higher Impairments and AI Investments Shape a New Capital Allocation Playbook for Charles River (CRL)?
Charles River Laboratories (CRL) reported first-quarter results showing modest revenue growth but a net loss and increased impairments, alongside a raised full-year GAAP EPS guidance. The company is actively reshaping its business through significant investments in AI-enabled digital pathology and cell therapy testing collaborations, aiming for improved efficiency and margin recovery. While these strategic shifts indicate a focus on higher-value services, investors are encouraged to consider the impact of rising cancellations and a book-to-bill ratio below 1x on the benefits of these initiatives.
DNA Methylation Sequencing Market to Reach USD 5.49 Billion
The global DNA Methylation Sequencing Market is projected to grow from USD 1.80 billion in 2025 to USD 5.49 billion by 2033, demonstrating a CAGR of 15.6%. This growth is fueled by increasing epigenetics research, rising prevalence of cancer and genetic disorders, and the growing adoption of precision medicine technologies. North America is expected to hold 43.1% of the market share, driven by advanced genomic research infrastructure and significant investments in cancer epigenetics.
Thermo Fisher Scientific Keeps Quarterly Dividend at $0.47 a Share, Payable July 15 to Shareholders of Record on June 15
Thermo Fisher Scientific announced that it will maintain its quarterly dividend at $0.47 per share. The dividend is scheduled to be paid on July 15 to shareholders who are on record as of June 15. This news was published on May 20, 2026, at 05:14 pm EDT.
Illumina stock (US4523271090): corporate responsibility push after return to growth
Illumina has released its latest Corporate Responsibility Report, highlighting efforts in climate, inclusion, and genomic access, shortly after reporting a 4.8% year-over-year revenue increase in Q1 2026 to $1.09 billion. This marks a return to top-line growth and coincides with a strategic pivot towards clinically oriented applications like oncology diagnostics. The report emphasizes ESG considerations for investors and links them to the company's long-term resilience and competitive positioning in the genomics market.
Thermo Fisher Scientific (TMO) Declares Consistent Dividend of $0.47 Per Share
Thermo Fisher Scientific (TMO) announced a quarterly dividend of $0.47 per share, maintaining its previous payout, which reflects the company's commitment to returning value to shareholders and confidence in its financial stability. The company has a strong GF Score™ of 86/100, indicating good potential for long-term returns, supported by its profitability and growth. However, recent insider selling and a modest dividend yield are noted, advising investors to proceed with caution.
Pixie Dust Technologies Raises Approximately ¥3.3 Billion in Series D Funding
Pixie Dust Technologies, a company specializing in healthcare and spatial acoustics using wave control technology, has raised approximately ¥3.3 billion in Series D funding. The capital, secured through third-party allotment, venture debt, and a syndicated loan, will be used to expand sales channels, promote R&D, develop new products, and enter global markets. Incubate Fund and Itochu Technology Ventures participated in the funding round.
Thermo Fisher Scientific Announces Quarterly Dividend - May 20, 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share. This dividend is payable on July 15, 2026, to shareholders of record as of June 15, 2026. The company, a leader in science, has annual revenue exceeding $45 billion, with a mission to enable healthier, cleaner, and safer environments through its services and products.
SomaLogic stock (US82489T1043): merger with Standard BioTools reshapes proteomics player
SomaLogic has completed an all-stock merger with Standard BioTools, creating a new life-science tools group focused on proteomics and genomics. This strategic move aims to diversify their offerings, enhance scale, and reduce costs. The combined entity seeks to leverage its expanded platform to drive growth in the multi-omics market while navigating integration challenges and competitive pressures.
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day
Thermo Fisher Scientific hosted its 2026 Investor Day, where Chairman and CEO Marc N. Casper emphasized the company's industry leadership and its essential role for customers globally. The company highlighted attractive end markets fueled by long-term trends, its proven growth strategy driven by innovation, and the accelerating impact of AI on scientific breakthroughs and productivity. Thermo Fisher also reiterated its commitment to disciplined capital deployment and an outstanding long-term outlook, expecting to deliver 7% organic revenue CAGR and low-teens adjusted EPS growth.
Thermo Fisher Scientific Announces Quarterly Dividend
Thermo Fisher Scientific Inc. (NYSE: TMO) announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share. This dividend is payable on July 15, 2026, to shareholders of record as of June 15, 2026. The company, a world leader in serving science, has annual revenue over $45 billion and aims to help customers make the world healthier, cleaner, and safer.
Press Release: Thermo Fisher Scientific Announces Quarterly Dividend
Thermo Fisher Scientific (NYSE: TMO) has announced its quarterly cash dividend of $0.39 per common share. This dividend is payable on July 12, 2024, to shareholders of record as of June 14, 2024. The consistent declaration of dividends reflects the company's commitment to returning value to its shareholders.
Thermo Fisher to pay $0.47 per share dividend on July 15
Thermo Fisher Scientific Inc. (NYSE: TMO) has announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share. This dividend is payable on July 15, 2026, to shareholders of record as of June 15, 2026. The company, a world leader in serving science with over $45 billion in annual revenue, reaffirms its commitment to returning value to shareholders.
Thermo Fisher Scientific Announces Quarterly Dividend
Thermo Fisher Scientific Inc. announced that its Board of Directors has authorized a quarterly cash dividend of $0.47 per common share. This dividend is payable on July 15, 2026, to shareholders of record as of June 15, 2026. The company is a world leader in serving science with annual revenue over $40 billion, committed to enabling customers to make the world healthier, cleaner, and safer.
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test - Guardant Health (NASDAQ:GH)
Guardant Health received FDA approval for its Guardant360 Liquid CDx test, an expanded liquid biopsy panel for advanced cancer patients. This updated test, powered by the proprietary Smart Platform, combines genomic and epigenomic insights from a single blood sample, offering faster turnaround times and broader clinical utility. The approval also transfers seven previous companion diagnostic indications to the new test, which features a 100 times wider genomic footprint than its predecessor.
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation
Thermo Fisher Scientific (NYSE: TMO) held its Investor Day, where Chairman and CEO Marc N. Casper emphasized the company's strong industry leadership, essential products, and growth strategy. The company highlighted its position in attractive end markets, its Practical Process Improvement (PPI) Business System, the accelerating role of AI, and its disciplined capital deployment. Thermo Fisher projects a 7% organic revenue CAGR and low-teens adjusted EPS growth long-term.
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day
Thermo Fisher Scientific hosted its 2026 Investor Day, where leadership discussed the company's strong industry position, growth strategy, and long-term value creation. Key highlights included attractive end markets, a proven growth strategy driven by innovation and a robust commercial engine, operational excellence through the PPI Business System, and the accelerating impact of AI on scientific breakthroughs and productivity. The company also emphasized its disciplined capital deployment approach and projected a 7% organic revenue CAGR and low-teens adjusted EPS growth long-term.
Thermo Fisher targets a $255B science market as AI reshapes drug discovery
Thermo Fisher Scientific highlighted its industry leadership, growth outlook, and long-term value creation at its 2026 Investor Day. The company serves an attractive $255 billion market, emphasizing its ability to leverage AI to accelerate scientific breakthroughs and improve drug discovery productivity. Thermo Fisher projects a 7% organic revenue CAGR and low-teens adjusted EPS growth over the long term.
SA News | SEABRIDGE GOLD INC (NYSE:SA)
This article provides recent news and analysis for Seabridge Gold Inc. (NYSE: SA), including its current stock price and links to articles discussing coiled springs and strategic projects in critical mineral supply. The stock recently closed at $29.88, down 2.51%.
Trump Has Been Investing in Companies and Then Pumping Them in His Speeches
Former President Trump has been found to invest in companies and then promote them in his public speeches, often on the same day as his stock purchases. This pattern of behavior, which includes investments in Thermo Fisher Scientific, Apple, Micron, and Dell, raises significant ethical concerns about financial self-dealing and a potential conflict of interest. Despite claims that his trades are managed by independent advisors, multiple "unsolicited" transactions suggest his direct involvement, leading to bipartisan calls for legislation to prevent such activity by elected officials.
Thermo Fisher Scientific expands global biobank leadership through strategic collaboration with PRECISE-SG100K Singapore to advance population-scale proteomics
Thermo Fisher Scientific is collaborating with Precision Health Research, Singapore (PRECISE) to support its PRECISE-SG100K study, a major population-scale biobank initiative. This partnership focuses on advancing population-scale proteomics to improve disease detection, prevention, and personalized care. The collaboration will integrate Thermo Fisher's Olink® Proximity Extension Assay platforms and Orbitrap Astral mass spectrometry system with Seer’s Proteograph® Product Suite to provide comprehensive proteomic analysis, enabling the translation of biological data into new disease mechanisms and biomarker insights.
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market
Thermo Fisher Scientific Inc. (TMO) stock increased by 1.31% to $447.81 on Tuesday, outperforming a broadly negative market where the S&P 500 and Dow Jones Industrial Average both fell. This marks the second consecutive day of gains for the stock.
Thermo Fisher Stock Down 31% From Its 52-Week High Despite Raising Full-Year EPS Guidance. Here’s What Happened
Thermo Fisher Scientific (TMO) stock has dropped 31% from its 52-week high despite reporting a Q1 2026 earnings beat and raising full-year EPS guidance. The decline is attributed to management's warning that academic and government demand for life-science tools will remain suppressed through the year, pushing recovery expectations into 2027 for that segment. Despite this, analysts maintain 24 buy-side ratings, anticipating a recovery in other segments and valuation models suggesting the stock is undervalued.
Thermo Fisher Mikroskop: What US labs need to know
This article details Thermo Fisher Mikroskop products, emphasizing their central role in laboratory imaging for US facilities. It covers their use in routine quality checks to advanced research, explaining how they help labs precisely see, measure, and document samples. The piece also highlights the significance of these microscopy tools for consumers and industry in academic, industrial, and clinical settings across the US and globally.
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
The global Cell Culture Media Market is projected to grow from USD 3.7 billion in 2026 to USD 7.1 billion by 2036, driven by rising biologics production, expanding cell and gene therapy pipelines, and increasing adoption of serum-free formulations. Key players like Avantor, Thermo Fisher Scientific, and Lonza Group AG are focusing on scalable GMP production and advanced media platforms to meet demand. The serum-free media segment and cancer research application are expected to lead market growth, with China, Japan, and Germany showing the fastest regional expansion.
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
The global Cell Culture Media Market is projected to grow from USD 3.7 billion in 2026 to USD 7.1 billion by 2036, at a CAGR of 6.6%. This growth is driven by the increasing demand for biologics, cell and gene therapies, and the shift towards serum-free formulations, with key players including Avantor, Thermo Fisher Scientific, and Lonza Group AG. The market focuses on scalable, GMP-grade manufacturing inputs, with significant growth expected in Asia-Pacific markets like China and Japan, as well as European countries and the US.
BioCardia Reports Promising CardiAMP Cell Therapy Data in Q1 2026 Conference Call
BioCardia discussed positive results for its CardiAMP Cell Therapy for ischemic heart failure during its Q1 2026 conference call. Blinded echocardiography data from the CardiAMP Heart Failure trial, analyzed by Yale University, showed treated patients maintained stable heart volumes, unlike control subjects. The therapy, which has FDA breakthrough designation and Medicare reimbursement, showed statistically significant benefits in a subgroup with elevated heart stress biomarkers, aligning with a composite endpoint for improved long-term outcomes.
American Tower (NYSE:AMT) Stock Unloaded Rep. Dwight Evans
Representative Dwight Evans (Democratic-Pennsylvania) recently sold American Tower (NYSE:AMT) shares worth $1,001 to $15,000 on May 11th, according to a May 15th filing. This insider selling comes despite American Tower reporting strong quarterly results, beating EPS and revenue estimates, and raising its full-year guidance and quarterly dividend. However, the company's dividend payout ratio is currently above 100%, and insiders have been net sellers recently.
Quanta Services (NYSE:PWR) Shares Unloaded Rep. Dwight Evans
Representative Dwight Evans (D-PA) sold between $1,001 and $15,000 worth of Quanta Services (NYSE:PWR) stock on May 7th, part of several recent stock sales. This sale happened despite Quanta Services reporting strong quarterly earnings with revenue exceeding estimates. Wall Street analysts maintain a "Moderate Buy" rating for PWR, with an average price target of $708.05.
Thermo Fisher Scientific expands global biobank leadership through strategic collaboration with PRECISE-SG100K Singapore to advance population-scale proteomics
Thermo Fisher Scientific has announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance the PRECISE-SG100K study, one of the region's largest population-scale biobank initiatives. This partnership aims to leverage multi-omic platforms and AI-driven analytics, integrating Thermo Fisher's Olink® Proximity Extension Assay (PEA) platforms and Orbitrap Astral mass spectrometry system with Seer’s Proteograph® Product Suite. The goal is to accelerate the path from discovery to translational insight in precision medicine, enabling earlier disease detection, prevention, and personalized care.
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden
Thermo Fisher Scientific has opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, specifically within GoCo Health Innovation City. This expansion aims to enhance the company's global bioanalytical capabilities and support pharmaceutical and biotechnology customers through all phases of drug development. The state-of-the-art facility, equipped with advanced technologies, will provide rapid and reliable bioanalytical services for both small molecules and complex therapeutic modalities, reinforcing Thermo Fisher's commitment to accelerating innovation in life sciences.
Thermo Fisher Sci. stock (US8835561023): Lab demand and U.S. biotech exposure stay in focus
Thermo Fisher Scientific remains a key U.S. life sciences stock due to its central role in the laboratory and biopharma supply chain. The company's performance is influenced by lab equipment demand, biopharma spending, and its broad product portfolio serving various sectors. Understanding Thermo Fisher's business model and market position offers insights into the broader scientific tools ecosystem and U.S. healthcare innovation.
Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research
The global Luminex Multiplex Assays Market is projected to reach USD 3.89 billion by 2033, growing at a CAGR of 10.0% from its 2025 valuation of USD 1.82 billion. This growth is driven by the increasing adoption of multiplex assay technologies for high-throughput biomarker profiling, the rising demand for panel scalability, and the shift towards standardized, throughput-oriented laboratory workflows across various sectors including clinical diagnostics, pharmaceutical research, and academic research. The market overview details its focus on bead-based multiplex immunoassay technologies and outlines key drivers, opportunities, challenges, and competitive landscape, with North America leading regional contributions.
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with Ne
Thermo Fisher Scientific has opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, significantly expanding its global bioanalytical capabilities. This state-of-the-art facility, located within GoCo Health Innovation City, will support pharmaceutical and biotechnology customers through all phases of drug development with rapid and reliable services for complex therapeutic modalities. The investment reinforces Thermo Fisher's commitment to the Swedish life sciences ecosystem and aims to accelerate innovation in drug development.
Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research
The Luminex Multiplex Assays Market is projected to reach USD 3.89 Billion by 2033, growing from USD 1.82 Billion in 2025 at a CAGR of 10.0%. This growth is fueled by increasing demand for high-throughput biomarker profiling, standardized multiplex testing workflows, and the growing adoption of these technologies in clinical diagnostics, pharmaceutical research, and CRO environments. The market's expansion is also supported by the efficiency of multiplex testing in reducing sample requirements and accelerating study iterations, alongside the increasing need for standardized and regulated panels.
Kyverna Therapeutics Appoints Greg Martini CFO Ahead of Potential Commercial Launch
Kyverna Therapeutics has appointed Greg Martini as its new Chief Financial Officer, effective May 18, 2026. Martini, previously CFO at Ironwood Pharmaceuticals, will oversee financial strategy as Kyverna prepares for the potential commercial launch of miv-cel, its CAR T-cell therapy for autoimmune disorders. This move signifies Kyverna's transition from clinical development to commercialization in the growing autoimmune and neuroimmunology cell therapy market.
Do Wall Street Analysts Like Thermo Fisher Scientific Stock?
Thermo Fisher Scientific Inc. (TMO) has underperformed the broader market and the healthcare sector over the past year and year-to-date. Despite beating Q1 earnings and revenue estimates, the stock dropped after management's cautious outlook on academic, government, and diagnostics demand, particularly in the U.S. and China. However, analysts maintain a "Strong Buy" consensus rating with significant upside potential based on current price targets.
Avantor (AVTR) Fell as Destocking Has Lasted Longer Than Expected
Broyhill Asset Management reported that its investment in Avantor, Inc. (AVTR) was a detractor in Q1 2026, primarily due to a longer-than-expected destocking cycle and management's failure to compete with Thermo Fisher. The firm has since redeployed its capital from Avantor into Sotera Health. Despite Avantor's revenue of $1.58 billion in Q1 2026, hedge fund interest in the company has decreased.
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden
Thermo Fisher Scientific has opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, enhancing its global capabilities to support drug development. This state-of-the-art facility, located in GoCo Health Innovation City, offers comprehensive services from preclinical to post-approval stages, including advanced technologies for complex therapeutic modalities. The expansion reinforces Thermo Fisher's commitment to the Swedish life sciences ecosystem and aims to accelerate innovation in drug development.
